Primary |
Psoriasis |
63.6% |
Product Used For Unknown Indication |
16.5% |
Psoriatic Arthropathy |
4.0% |
Hypertension |
3.3% |
Diabetes Mellitus |
1.8% |
Ill-defined Disorder |
1.6% |
Prophylaxis |
1.4% |
Depression |
1.4% |
Pain |
1.2% |
Pustular Psoriasis |
0.8% |
Drug Use For Unknown Indication |
0.7% |
Crohn's Disease |
0.6% |
Anxiety |
0.5% |
Hyperlipidaemia |
0.5% |
Hypothyroidism |
0.4% |
Blood Cholesterol Increased |
0.4% |
Pruritus |
0.4% |
Blood Cholesterol |
0.3% |
Arthritis |
0.3% |
Asthma |
0.3% |
|
Psoriasis |
15.8% |
Myocardial Infarction |
12.8% |
Pneumonia |
9.6% |
Cerebrovascular Accident |
5.5% |
Cellulitis |
4.6% |
Psoriatic Arthropathy |
4.6% |
Pustular Psoriasis |
4.4% |
Off Label Use |
4.2% |
Prostate Cancer |
4.2% |
Weight Decreased |
4.0% |
Headache |
3.8% |
Death |
3.8% |
Herpes Zoster |
3.4% |
Drug Ineffective |
3.4% |
Weight Increased |
3.0% |
Tuberculosis |
3.0% |
Breast Cancer |
2.5% |
Hepatic Enzyme Increased |
2.4% |
Hepatic Function Abnormal |
2.4% |
Liver Function Test Abnormal |
2.4% |
|
Secondary |
Psoriasis |
73.1% |
Product Used For Unknown Indication |
7.9% |
Psoriatic Arthropathy |
6.4% |
Hypertension |
2.5% |
Prophylaxis |
1.9% |
Crohn's Disease |
1.9% |
Diabetes Mellitus |
1.0% |
Ill-defined Disorder |
0.9% |
Pustular Psoriasis |
0.8% |
Depression |
0.6% |
Hyperlipidaemia |
0.5% |
Pain |
0.4% |
Folliculitis |
0.4% |
Anticoagulant Therapy |
0.3% |
Convulsion Prophylaxis |
0.2% |
Hyperuricaemia |
0.2% |
Asthma |
0.2% |
Hypothyroidism |
0.2% |
Contraception |
0.2% |
Hidradenitis |
0.2% |
|
Psoriasis |
20.6% |
Hepatic Function Abnormal |
8.7% |
Cellulitis |
6.7% |
Myocardial Infarction |
6.2% |
Pneumonia |
5.7% |
Drug Ineffective |
4.9% |
Off Label Use |
4.9% |
Psoriatic Arthropathy |
4.9% |
Cerebrovascular Accident |
3.9% |
Neck Pain |
3.9% |
Weight Decreased |
3.7% |
Liver Disorder |
3.6% |
Syncope |
3.1% |
Nasopharyngitis |
2.9% |
Type 2 Diabetes Mellitus |
2.9% |
Gamma-glutamyltransferase Increased |
2.8% |
Condition Aggravated |
2.7% |
Gastroenteritis |
2.7% |
Liver Function Test Abnormal |
2.7% |
Staphylococcal Infection |
2.6% |
|
Concomitant |
Psoriasis |
51.9% |
Product Used For Unknown Indication |
13.3% |
Psoriatic Arthropathy |
10.5% |
Anxiety |
4.6% |
Depression |
3.9% |
Crohn's Disease |
2.8% |
Post Concussion Syndrome |
2.6% |
Prophylaxis |
1.5% |
Pain |
1.1% |
Rheumatoid Arthritis |
1.1% |
Vitamin Supplementation |
1.1% |
Hypertension |
0.9% |
Post-traumatic Pain |
0.9% |
Thyroid Disorder |
0.9% |
Hypersensitivity |
0.7% |
Parkinson's Disease |
0.7% |
Acute Psychosis |
0.4% |
Dyspepsia |
0.4% |
Hypothyroidism |
0.4% |
Low Density Lipoprotein Increased |
0.4% |
|
Psoriasis |
37.7% |
Drug Ineffective |
20.3% |
Therapeutic Response Decreased |
9.4% |
Skin Plaque |
4.3% |
Pancreatic Carcinoma |
2.9% |
Pancreatitis |
2.9% |
Psoriatic Arthropathy |
2.9% |
Weight Decreased |
2.2% |
Acute Psychosis |
1.4% |
Arthritis |
1.4% |
Crohn's Disease |
1.4% |
Drug Interaction |
1.4% |
Gastrointestinal Haemorrhage |
1.4% |
Headache |
1.4% |
Hypertension |
1.4% |
Injection Site Pain |
1.4% |
Prostate Cancer |
1.4% |
Pyrexia |
1.4% |
Rash |
1.4% |
Skin Exfoliation |
1.4% |
|
Interacting |
Psoriasis |
90.0% |
Hyperlipidaemia |
10.0% |
|
Psoriasis |
57.1% |
Ataxia |
14.3% |
Drug Level Increased |
14.3% |
Myalgia |
14.3% |
|